Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sisonke 4 (SHERPA) heterologous Moderna booster study
PACTR202310615330649Phase 3Unknown
- Sponsor
- Moderna Inc
- Start
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of elasomeran in coronavirus disease 2019 (COVID-19), sponsored by Moderna Inc. Primary endpoints: Effectiveness against severe COVID-19 and Effectiveness against any COVID-19. Status: unknown.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202310615330649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202310615330649.